Navigation Links
RegeneCure Starts Clinical Study Using Polymeric Bone Stimulating Membrane for Dental Implants
Date:6/18/2013

in order to provide clinical data for potential use in both smoking and non-smoking populations.

The study will examine if RegeneCure's membrane enables a similar or better amount of lateral bone fill compared with the collagen membrane which is considered the gold standard treatment today. Each patient will be followed over a 6-month period.

The Principal Investigators are  Prof. Lior Shapira, Chairman of the Department of Periodontology at the Hadassah  Medical Center, Jerusalem, Israel and Prof. Eli Machtei, Director of the  Dept. of Oral Medicine & Periodontology at the Rambam Medical Center in Haifa, Israel.

The AMCA membrane is thin and flexible, drill-able, and easily sutured in the treated area. It is easy to use in orthopedic surgery and requires no special surgical knowledge or special preparation prior to use.

About the Market

The global dental implants market is set to almost double in value over the next six years, owing to the aging population and the availability of advanced solutions for dental implants in conjunction with oral regenerative tissue products. Global sales of dental implant systems reached more than $3.4 billion in 2012 with Europe (49%) as largest market before the United States (31%). In 2012, the global dental membrane market was over $200 million with annual growth of 5-10% to reach $300 million by 2017.

About  RegeneCure

RegeneCure Ltd. was founded in July 2010 to develop, produce and market synthetic implants for bone reconstruction and fracture fusion for the orthopedic, dental and aesthetic fields. AMCA Membrane Implant technology is protected by worldwide patents. The company submitt
'/>"/>

SOURCE RegeneCure Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Mexican State of Tamaulipas Starts Training Doctors in Sangui Wound Management
2. Lab course that starts with students own ideas wins Science magazine prize
3. Management Matters Series Starts with “Lab Budgeting 101”
4. Week One of All Things Medical Auction Event Starts Monday, March 11, 2013 Conducted by IpAuctions™, Inc.
5. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
6. Positive Clinical Study Results for BSPs HyperQ Technology
7. DermTechs Non-invasive Melanoma Detection Assay Poised to Enter Clinical Validation Study
8. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
9. AtheroNova Inc. Preclinical Study Demonstrates 95% Reduction in Arterial Plaque Formation
10. A New Type of Dendritic Cell-Based Cancer Vaccine has Received Approval for Clinical Tests and at the Same Time Secures Substantial Financing
11. Generex Provides Update on Generex Oral-lyn™ Clinical & Regulatory Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... HILL, N.C. , Dec. 22, 2014 /PRNewswire/ ... today announced that it has signed a letter ... company that has developed and patented a nanotechnology-based ... medical diagnostics products that enable rapid on-site collection ... alcohol use/abuse and health issues in an immediate, ...
(Date:12/22/2014)... MISSION VIEJO, Calif. , Dec. 22, 2014 /PRNewswire/ ... announce that CoPatient, an online medical bill review and ... newest offering in the FREE WellCard Savings discount health ... a medical bill that was more than they expected ... help members reduce health care costs, WellCard Savings is ...
(Date:12/22/2014)... Illinois (PRWEB) December 22, 2014 ITRA ... tenants and occupiers of commercial real estate, has further ... new offices in Perth and Brisbane, Western Australia, reports ... of directors. , ITRA Global / ACORPP (Australian ... totally independent consultancy company providing property services to a ...
(Date:12/19/2014)... OR and Hershey, PA (PRWEB) December 19, 2014 ... Pink: BJCT), a leading developer and manufacturer of ... entered into an agreement with Immunomic Therapeutics, Inc. ... Biojector®-2000 needle-free injection device with its LAMP™ vaccine ... an option for an exclusive Worldwide license to ...
Breaking Biology Technology:ALNE Announces Intention To Acquire BioTechPharma 2WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2ITRA Global Continues International Expansion in Perth and Brisbane, Australia 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3
... , July 13 MacroGenics, Inc. today announced ... clinical study evaluating MGAWN1, a humanized monoclonal antibody, for ... infection due to West Nile Virus (WNV). MacroGenics, ... treat autoimmune disorders, cancer and infectious diseases, was awarded ...
... PCT ... , ... July 13, 2009 -- Progenitor Cell Therapy, LLC (PCT) today announced the recent appointment ... of Manufacturing Operations, Daryl is responsible for managing and supervising the day-to-day conduct of ...
... a network of tiny sensors as small as dewdrops called ... Scattered outdoors on rocks, fence posts and doorways, or ... a completely new and cost-effective system for safeguarding and securing ... Tel Aviv University Faculty of Engineering team drew upon the ...
Cached Biology Technology:MacroGenics Announces the Initiation of a Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Monoclonal Antibody MGAWN1 in Subjects with Suspected Central Nervous System Infection Due to West Nile Virus 2MacroGenics Announces the Initiation of a Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Monoclonal Antibody MGAWN1 in Subjects with Suspected Central Nervous System Infection Due to West Nile Virus 3MacroGenics Announces the Initiation of a Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Monoclonal Antibody MGAWN1 in Subjects with Suspected Central Nervous System Infection Due to West Nile Virus 4Progenitor Cell Therapy Appoints VP of Manufacturing Operations 2Progenitor Cell Therapy Appoints VP of Manufacturing Operations 3Intruder alert: Tel Aviv University's 'Smart Dew' will find you! 2
(Date:12/17/2014)... Valencell, a leader in performance biometric data ... industry leaders such as Intel, Jabra, Atlas, and Scosche ... products. These products will be showcased at CES 2015, ... . "Our partners choose PerformTek ... – with the clinical data to back it up," ...
(Date:12/11/2014)... Research and Markets , ... http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition of the ... to their offering. One major ... of multimodal biometric systems. Multimodal biometric systems utilize ... verification and identification purposes. This helps to reduce ...
(Date:12/10/2014)... 9, 2014  Wake Forest Baptist Medical Center today announced ... School of Medicine. Funding for this $50 million capital ... will be publicly launched next summer. ... former 60 series R.J. Reynolds Tobacco Company complex, adjacent ... begin immediately with plans to be ready to welcome ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
... backdrop of some of the world,s most sophisticated biological research ... to his colleagues in Congress: immediately upon their return from ... reverse a recent Federal court decision that has brought embryonic ... Rep. Israel was seconded in his plea by Dr. ...
... Westminster, Colo. (August 27, 2010) Although having a ... factor for cardiovascular disease, researchers are only beginning to ... the development of the disease. Now, a study of ... Prevention Study (KEEPS), suggests that as BMI increases, so ...
... Rare but devastating, eye cancer can strike anyone at ... half of all patients partially blind. But a new ... University of Colorado School of Medicine, may change all that. ... eye can block up to 55 percent of harmful radiation, ...
Cached Biology News:Congressman, CSHL president urge quick action to reverse judicial embryonic stem cell research ban 2Congressman, CSHL president urge quick action to reverse judicial embryonic stem cell research ban 3Body mass index and thrombogenic factors in newly menopausal women 2Body mass index and thrombogenic factors in newly menopausal women 3Researcher finds revolutionary way to treat eye cancer 2
Goat polyclonal to SPFH2 ( Abpromise for all tested applications). Antigen: Synthetic peptide: EDEPLETATKEN, corresponding to C terminal amino acids 328-339 of Human SPFH2 Entrez Gene ID: 11...
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
alpha/beta-Tubulin Antibody Ship: Hot Store: -20 C...
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
Biology Products: